标题
PI3-Kinase Inhibitors in Chronic Lymphocytic Leukemia
作者
关键词
New targets, PI3K, PI3K delta, PI3K-δ, PI3K Gamma, PI3K-γ, CAL-101, GS-1101, Idelalisib, INK-1197, IPI-145, Chronic lymphocytic leukemia, Small lymphocytic lymphoma
出版物
Current Hematologic Malignancy Reports
Volume 9, Issue 1, Pages 33-43
出版商
Springer Nature
发表日期
2014-01-06
DOI
10.1007/s11899-013-0189-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Isoform-Specific Functions of Phosphoinositide 3-Kinases: p110 but Not p110 Promotes Optimal Allergic Responses In Vivo
- (2014) K. Ali et al. JOURNAL OF IMMUNOLOGY
- Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
- (2013) Klaus Okkenhaug Annual Review of Immunology
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibitors of B-Cell Receptor Signaling for Patients With B-Cell Malignancies
- (2012) Michael Y. Choi et al. CANCER JOURNAL
- Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
- (2012) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia
- (2012) Ines M. Macias-Perez et al. Current Hematologic Malignancy Reports
- Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
- (2011) A Smith et al. BRITISH JOURNAL OF CANCER
- Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
- (2011) Michael C. Schmid et al. CANCER CELL
- Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2011) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma
- (2010) Trevor W. Dennie et al. CLINICAL THERAPEUTICS
- Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
- (2010) Bruce D. Cheson JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
- (2009) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia
- (2009) Wolfgang U. Knauf et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started